Skip to main content

Salkind Gene

In the past year, 2 open-market purchase filings worth $673.5K and no sales.

Current role at each company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
$673.5K
2 filings
Sold
–
0 filings
Net
+$673.5K
Bought minus sold
Companies
1
With open-market trades

Trades

Every Form 4 that lists Salkind Gene as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

UPXI Upexi, Inc.

Director6 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 21, 2025 (view filing)Nov 201 daySalkind GeneDirectorPPurchase+50.0K$2.55+$127.5K+29.6%218.8K after
Nov 18, 2025 (view filing)Nov 171 daySalkind GeneDirectorPPurchase+100.0K$2.65+$265.0K+21.3%569.5K after
Nov 18, 2025 (view filing)Nov 171 daySalkind GeneDirectorPPurchase+100.0K$2.81+$281.0K+145.5%168.8K after
Jul 30, 2025 (view filing)Jul 1119 daysLateSalkind GeneDirector, 10% OwnerPPurchase+20.2K$4.94+$100.0K+5.5%385.4K after
Apr 25, 2025 (view filing)Apr 178 daysLateSalkind GeneDirector, 10% OwnerPPurchase+241.2K$2.28+$550.0K+194.7%365.1K after
Apr 1, 2022 (view filing)Mar 302 daysSalkind GeneDirector, 10% OwnerPPurchase+125.0K$4.00+$500.0KNew position125.0K after

ZSQR Z Squared Inc.

Director2 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jan 9, 2024 (view filing)Jan 54 daysSalkind GeneDirectorPPurchase+11.6K$0.69+$8.00K+4.3%284.1K after
Aug 30, 2023 (view filing)Aug 25-295 daysLateSalkind GeneDirectorPPurchase+32.6K$0.9223+$30.1KNew position4.05K after2 lots